{"log_id": 8287364161507866991, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 1.6e-05, "average": 0.997627, "min": 0.978513}, "location": {"width": 839, "top": 156, "height": 50, "left": 166}, "words": "用于治疗成人复发的或难治的费城染色体阳性的急性淋巴细胞白血病(Ph+ALL)"}, {"probability": {"variance": 0.007823, "average": 0.970569, "min": 0.523098}, "location": {"width": 786, "top": 206, "height": 48, "left": 168}, "words": "用于治疗嗜酸细胞过多综合症(HES)和/或慢性嗜酸粒细胞白血病(CEL)伴有"}, {"probability": {"variance": 0.012388, "average": 0.928319, "min": 0.634948}, "location": {"width": 409, "top": 264, "height": 41, "left": 137}, "words": "FIP1L1- PDGFR a融合激酶的成年患者"}, {"probability": {"variance": 0.00268, "average": 0.988506, "min": 0.673732}, "location": {"width": 891, "top": 302, "height": 49, "left": 172}, "words": "用于治疗骨髓增生异常综合症/骨髓增生性疾病( MDS/MPD)伴有血小板衍生生长因子"}, {"probability": {"variance": 0.003453, "average": 0.977444, "min": 0.773629}, "location": {"width": 366, "top": 362, "height": 40, "left": 92}, "words": "受体( PDGFR)基因重排的成年患者"}, {"probability": {"variance": 0.000113, "average": 0.993292, "min": 0.947254}, "location": {"width": 894, "top": 397, "height": 50, "left": 173}, "words": "用于治疗侵袭性系统性肥大细胞增生症(ASM),无D816Vc-Kit基因突变或未知c-Kit"}, {"probability": {"variance": 0, "average": 0.999485, "min": 0.998539}, "location": {"width": 220, "top": 461, "height": 34, "left": 94}, "words": "基因突变的成人患者"}, {"probability": {"variance": 0.000178, "average": 0.995564, "min": 0.924296}, "location": {"width": 733, "top": 495, "height": 46, "left": 174}, "words": "用于治疗不能切除,复发的或发生转移的隆突性皮肤纤维肉瘤(DFSP)"}, {"probability": {"variance": 0, "average": 0.999474, "min": 0.998296}, "location": {"width": 132, "top": 559, "height": 29, "left": 103}, "words": "【规格】"}, {"probability": {"variance": 0.001337, "average": 0.97741, "min": 0.874298}, "location": {"width": 232, "top": 603, "height": 32, "left": 149}, "words": "01g(按C29H31N7O计)"}, {"probability": {"variance": 2e-06, "average": 0.998776, "min": 0.996623}, "location": {"width": 131, "top": 653, "height": 31, "left": 106}, "words": "【用法用量】"}, {"probability": {"variance": 1e-06, "average": 0.999572, "min": 0.997394}, "location": {"width": 509, "top": 692, "height": 42, "left": 148}, "words": "治疗应由对恶性肿瘤患者有治疗经验的医师进行"}, {"probability": {"variance": 1e-06, "average": 0.999335, "min": 0.996343}, "location": {"width": 872, "top": 732, "height": 49, "left": 148}, "words": "甲磺酸伊马替尼应在进餐时服用,并饮一大杯水,以使胃肠道紊乱的风险降到最小"}, {"probability": {"variance": 8.6e-05, "average": 0.996892, "min": 0.938137}, "location": {"width": 928, "top": 781, "height": 50, "left": 146}, "words": "通常成人每日一次,每次400mg或600mg,以及日服用量800mg即400mg剂量每天2"}, {"probability": {"variance": 0.000185, "average": 0.994521, "min": 0.940834}, "location": {"width": 731, "top": 832, "height": 47, "left": 102}, "words": "次(在早上及晚上)。儿童和青少年每日一次或分两次服用(早晨和晚上"}, {"probability": {"variance": 4.3e-05, "average": 0.99716, "min": 0.968025}, "location": {"width": 928, "top": 880, "height": 48, "left": 149}, "words": "不能吞咽药片的患者(包括儿童),可以将药片分散于不含气体的水或苹果汁中(100mg"}, {"probability": {"variance": 0.004637, "average": 0.981794, "min": 0.622083}, "location": {"width": 860, "top": 926, "height": 52, "left": 103}, "words": "片约用50ml,400mg约用200m).应搅拌混悬液,一旦药片崩解完全应立即服用"}, {"probability": {"variance": 9e-06, "average": 0.99798, "min": 0.990988}, "location": {"width": 437, "top": 982, "height": 40, "left": 154}, "words": "只要患者持续受益,本品治疗应持续进行"}, {"probability": {"variance": 0.000304, "average": 0.988975, "min": 0.94078}, "location": {"width": 280, "top": 1035, "height": 37, "left": 105}, "words": "Ph+CML患者的治疗剂量"}, {"probability": {"variance": 0, "average": 0.983616, "min": 0.983616}, "location": {"width": 115, "top": 998, "height": 110, "left": 768}, "words": "但"}, {"probability": {"variance": 0, "average": 0.999693, "min": 0.999524}, "location": {"width": 49, "top": 1090, "height": 28, "left": 108}, "words": "成人"}, {"probability": {"variance": 2.8e-05, "average": 0.997743, "min": 0.975095}, "location": {"width": 922, "top": 1118, "height": 49, "left": 154}, "words": "对慢性期患者甲磺酸伊马替尼的推荐剂量为400mg/日,急变期和加速期患者为600mg/"}, {"probability": {"variance": 0, "average": 0.999687, "min": 0.999687}, "location": {"width": 26, "top": 1187, "height": 26, "left": 110}, "words": "日"}, {"probability": {"variance": 0.001165, "average": 0.984293, "min": 0.851164}, "location": {"width": 923, "top": 1213, "height": 51, "left": 155}, "words": "对于WBC>500001的CML患者的一线治疗,治疗经验仅限于曾接受过羟基脲治疗的"}, {"probability": {"variance": 0, "average": 0.999666, "min": 0.99867}, "location": {"width": 558, "top": 1268, "height": 45, "left": 110}, "words": "患者。该治疗开始可能需要加上甲磺酸伊马替尼治疗"}, {"probability": {"variance": 0.00021, "average": 0.994977, "min": 0.917811}, "location": {"width": 923, "top": 1309, "height": 50, "left": 158}, "words": "没有严重药物不良反应且如果血象许可,在下列情况下剂量可考虑从400mg/日增加到"}, {"probability": {"variance": 0.000181, "average": 0.994186, "min": 0.94901}, "location": {"width": 968, "top": 1355, "height": 56, "left": 113}, "words": "600mg/日,或从600mg/日增加到800mg/日:任何时间出现了疾病进展、治疗至少3个月后"}, {"probability": {"variance": 0.005274, "average": 0.98635, "min": 0.528041}, "location": {"width": 973, "top": 1403, "height": 54, "left": 113}, "words": "未能获得满意的血液学反应,治疗12个月未获得任何细胞遗传学反应,己取得的血液学和/"}, {"probability": {"variance": 2.8e-05, "average": 0.997822, "min": 0.980573}, "location": {"width": 294, "top": 1466, "height": 39, "left": 115}, "words": "或细胞遗传学反应重新消失"}, {"probability": {"variance": 0, "average": 0.999604, "min": 0.997757}, "location": {"width": 239, "top": 1517, "height": 34, "left": 116}, "words": "3岁以上儿童及青少年"}], "language": 3}